Full Year
NNVC — FY2026 Financial Report Analysis
NanoViricides narrowed its FY2026 net loss to $8.2M on lower lab and investor-outreach spending, but with $6.2M of cash after a July raise and a going-concern warning, its runway now hinges on Phase II mpox and Ebola trials that have yet to dose a patient.